Discover investment opportunities in Top Gene Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Gene Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Gene Editing Stocks using our Smart AI Filter.
9 stocks found for "Top Gene Editing Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 Risk measure | ±100.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
0.40 Risk measure | ±20.2% Price volatility | 20.9 Valuation | 7.10% Annual yield | |||
1.98 Risk measure | ±100.0% Price volatility | -2.4 Valuation | 0.00% Annual yield | |||
1.34 Risk measure | ±55.5% Price volatility | -10.4 Valuation | 0.00% Annual yield | |||
1.82 Risk measure | ±67.7% Price volatility | -15.1 Valuation | 0.00% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
0.71 Risk measure | ±36.2% Price volatility | 24.3 Valuation | 0.62% Annual yield | |||
0.37 Risk measure | ±22.9% Price volatility | 21.1 Valuation | 0.52% Annual yield | |||
1.92 Risk measure | ±68.6% Price volatility | -1.9 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes CRISPR Therapeutics (CRSP) a noteworthy gene editing stock?
A: CRISPR Therapeutics (CRSP) is a pioneer in the field, focusing on developing gene-based medicines. Its potential to edit genes precisely for treating various genetic disorders is a key attraction for growth-oriented investors.
Q: How does Editas Medicine (EDIT) address genetic disorders?
A: Editas Medicine (EDIT) leverages its proprietary gene editing technologies to design therapies that can directly modify faulty genes, targeting disorders with high unmet medical needs.
Q: What distinguishes Intellia Therapeutics (NTLA) from other gene editing companies?
A: Intellia Therapeutics (NTLA) is notable for its in vivo gene editing approach. This method allows for direct editing of genes inside the body, potentially expanding therapeutic applications.
Q: Why do investors consider Beam Therapeutics (BEAM) a significant player in gene editing?
A: Beam Therapeutics (BEAM) focuses on base editing, a technology believed to offer precision in correcting single base mutations, promising improved treatment outcomes.
Q: In terms of potential, how competitive is Caribou Biosciences (CRBU) in the gene editing sector?
A: Caribou Biosciences (CRBU) is competitive due to its CRISPR hybrid cell technology, designed to enhance the specificity and efficacy of gene edits, appealing to investors interested in innovation.
Q: What investment risks are associated with Verve Therapeutics (VERV)?
A: Verve Therapeutics (VERV) faces risks typical in biotech, such as regulatory hurdles, clinical trial failures, and the high costs associated with developing genetic therapies.